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Constitutive activation of mutant glycogen synthase in equine type 1 polysaccharide 
storage myopathy explains the gain of function disease mechanism in a highly prevalent 
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Summary 
Equine type 1 polysaccharide storage myopathy (PSSM1) is associated with a missense, founder 
mutation (R309H) in the GYS1 glycogen synthase  gene, excessive glycogen and amylopectate-
like inclusions in muscle, and higher muscle glycogen synthase (GS) activities than in controls; 
however, the causative mechanisms remain unclear. GS is allosterically regulated by glucose-6-
phosphate (G6P) and enzyme activity is reduced by phosphorylation. In this work, homology 
modelling, and equine muscle biochemical and recombinant enzyme kinetic assays in vitro were 
used to investigate the hypothesis that higher GS activity in affected horses is due to (1) a 
conformational structural change; (2) higher expression of the mutant enzyme; (3) reduced 
phosphorylation or (4) constitutive activation. 
PSSM1-affected horses had significantly higher muscle glycogen contents than controls. Despite 
no difference in total expression, GS activity was significantly higher in PSSM1-affected 
homozygotes than in heterozygotes and control horses in both the absence (p=0.04) and 
presence (p=0.03) of G6P. There was significantly more phosphorylation of GS at site 2+2a 
(p=0.009) and a significantly higher AMPK (an upstream kinase) expression (p=0.04) in PSSM1-
homozygotes compared to controls. In contrast to recombinant wild type enzyme, mutant GS was 
highly active, even at very low G6P concentrations. 
The mutant enzyme’s high activity, despite increased phosphorylation, even in the absence of 
G6P, reveals it to be constitutively active. Modelling suggests that the R309H mutation disrupts a 
salt bridge that normally stabilises the enzyme’s basal state, shifting the conformational 
equilibrium to the active state and explaining the gain-of-function pathogenesis in this highly 
prevalent disorder. 
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Introduction 
The ability to store glucose as the branched chain polymer glycogen is shared by organisms as 
evolutionarily diverse as bacteria and mammals:  it enables organisms to deal with temporary 
starvation by maintaining energy provision through glycogen catabolism, and, in times of plenty, 
to store this energy macromolecule substrate in a form that has minimal effect on cellular osmotic 
pressure [1]. In mammals, glycogen is normally stored in muscle and other tissues following the 
action of 2 enzymes: glycogen synthase (GS) and glycogen branching enzyme (GBE). GS 
catalyses the polymerisation of UDP-glucose monomers via α1-4 glycosidic bonds and GBE is 
responsible for generating α1-6 bonds, every 4-10 residues [2]. There are 2 GS isoforms; one, 
muscle glycogen synthase (MGS) is encoded by the GYS1 gene and predominantly expressed 
in muscle but also in other tissues; the other, liver glycogen synthase (LGS) is encoded 
specifically in liver, a product of the GYS2 gene. Both GS isoforms are regulated by 
phosphorylation and allosteric modulation by glucose-6-phosphate (G6P) [3].  
 
There are more than 14 glycogen storage diseases in humans and animals [4-7], several of which 
are characterised by excessive glycogen accumulation or abnormal glycogen structure caused 
by defects in glycogenesis or glycogenolysis. In 2008, a missense, autosomal dominant mutation 
(R309H) in GYS1 was identified in Quarter Horses with a form of exertional rhabdomyolysis 
known as polysaccharide storage myopathy (PSSM1), characterised by excessive glycogen and 
amylopectate accumulation in skeletal muscle [8] but without apparent cardiac signs [9]. Since 
then, the identical mutation has been reported in many horse breeds worldwide [10-13], 
suggesting dissemination from a single founder, and there is evidence supporting positive 
selection for the mutation within certain breeds [14] which might be associated with the mutation’s 
effect on increasing enzyme activity [8]. Since the ratio of GS: GBE activity is important in 
formation of glycogen with a normal structure [15], filamentous alpha crystalline polysaccharide 
that forms in PSSM1-affected muscle likely develops due to an increased GS: GBE activity [16]. 
However, the mechanism by which the R309H mutation results in increased GS activity is 
unknown; potential mechanisms include elevated expression, reduced degradation or 
dysregulation of enzyme activity. Since mutation of an adjacent amino acid in the yeast GS 
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(equivalent to amino acid G310 in mammalian GS) also results in increased enzyme activity [17], 
mutations in this region might result in constitutive activation of the enzyme. 
 
Aberrant phosphorylation of the mutant enzyme might account for the increase in GS activity seen 
in horses with PSSM1 [8]. GS regulation is heavily dependent on 9 separate phosphorylation sites 
that are modified by various upstream kinases; of these, phosphorylation at sites 2 (serine residue 
S7), 2a (S10), 3a (S641) and 3b (S645) decrease the enzyme’s activity more than the remaining 
5 sites [18-20]. Furthermore, phosphorylation of certain sites enables sequential phosphorylation 
of others so that they can be functionally grouped for investigative purposes [21]. The 
phosphorylation sites are arranged into clusters where a primary site must be phosphorylated 
prior to sequential phosphorylation of the other surrounding sites in a process known as 
hierarchical phosphorylation [21]. Two of the key upstream kinases for GS are glycogen synthase 
kinase 3β (GSK3β) (which phosphorylates sites 3a, 3b, 3c, and 3d) and AMP-activated protein 
kinase (AMPK), which phosphorylates site 2. The phosphorylation of these sites markedly 
inactivate GS, whereas other upstream regulators, namely Casein Kinase 2 and Protein kinase 
A, are associated with phosphorylation as sites 1a, 1b and 5 which have little effect on GS activity 
[21].  
AMPK exists as a heterotrimer made up of an  catalytic , a  (regulatory) and a  (regulatory) 
subunit [23]. Both 1 and 2 forms are expressed in skeletal muscle but it is the 1 form that 
contributes mainly to AMPK activity at rest and the 2 form which increases in response to 
exercise, therefore suggesting the 1 form is the ‘basal’ form of the enzyme found in skeletal 
muscle [24]. The phosphorylation of GS can also have a significant effect on G6P affinity; indeed, 
regulation by G6P is associated with a feed-forward mechanism resulting in further enzyme 
activation by dephosphorylation [22]. Although the R309H residue is distant in the primary 
sequence from any of the known phosphorylation sites, the mutation could result in an 
inappropriate response to phosphorylation as is seen in a yeast GS variant [17]. Dranchak et al. 
examined activity of AMPK in horses with PSSM in comparison with controls (finding no 
difference) prior to identification of the equine GYS1 mutation [25], but expression or 
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phosphorylation of other upstream regulators, such as GSK3β, have not been investigated in this 
disorder.  
 
Although the crystal structure has not been published for any mammalian glycogen synthase, the 
structures for a bacterial GT5 synthase (Agrobacterium tumefaciens) [2] and, more recently, for 
a yeast synthase (Saccharomyces cerevisiae; Gsy2p) [26] and Caenorhabditis elegans [27] have 
been solved. Yeast GS is a homo-tetrameric protein in both its basal and active states and 
eukaryotic GT3 synthases likely have a similar tetrameric arrangement due to their high levels of 
sequence homology [26]. Since the amino acid sequence surrounding the PSSM1 R309H GYS1 
mutation is highly conserved amongst species, from yeast to horses [8] this site might have an 
important (but as yet unknown) functional role [2, 28], although it is not thought to be involved in 
substrate binding [2, 29] or catalytic activity [2, 17, 30]. 
 
The binding of the GS ligand, G6P is complex, given its dual roles as both an allosteric activator 
and substrate [26]. The structural basis for G6P allosteric activation has been revealed from 
analysis of high-resolution crystal structures of the homologous synthase enzyme, Gsy2p from 
Saccharomyces cerevisiae; GS has a binding pocket for the 6-phosphate side chain of G6P that 
comprises 5 residues that are conserved across the GT3 family glycosyltransferases [26]. 
Subsequently, G6P binding results in a major conformational change involving translation and 
rotation toward the tetramer interface of the enzyme to generate the active form [26]. Co-
crystallisation of Gsy2p with maltodextrin polymers (used as analogues to detect glycogen binding 
sites) shows that there are at least 4 maltodextrin sites for this substrate in the enzyme’s active 
form [31]. Only binding sites 1 and 2 are exposed in the basal form of GS [31]: these sites might 
be important for enabling the enzyme to remain bound to glycogen even when GS activity is 
reduced by phosphorylation [32]. 
 
Improved understanding of the mechanism by which a mutation in equine GYS1 leads to the 
mutant enzyme’s increased activity might help further elucidate the functional significance of a 
region of this fundamentally important mammalian enzyme. Furthermore, it might prompt 
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investigation of specific treatments for this common equine myopathy or for other related 
glycogenosis in humans [33]. In this work, we investigate the enzyme’s regulation in silico via 
computational modelling and through biochemical analysis in vitro of whole muscle extracts and 
via insect-derived recombinant enzyme kinetics.  We hypothesised that higher GS activity in 
PSSM1-affected horses might be due either to (1) a conformational change associated with ligand 
binding or to the active site; (2) increased expression or reduced degradation of the mutant 
enzyme, (3) reduced phosphorylation or (4) constitutive activation. 
 
Materials and Methods 
Muscle sample collection: 
Muscle samples were collected by open biopsy under local anaesthesia from the 
semimembranosus muscle of 12 normal (RR), 13 heterozygote (HR) and 4 homozygous mutant 
(HH) Belgian Draught and Percheron horses according to ethical approval from the Institutional 
Animal Care and Use Committee (University of Auburn). All horses were maintained at the 
University research facility and were managed at pasture and fed identically. Horses were 
selected on the basis of age- and sex-matching of individuals of differing genotype; following 
genotyping of the entire herd of horses using an established restriction fragment polymorphism 
assay [8]. Samples were snap-frozen in liquid nitrogen, shipped on dry ice and stored at -80oC 
until use. 
 
Glycogen content measurement: 
Total glycogen was measured in 50 mg wet weight muscle biopsy samples using a commonly 
used colorimetric assay [34] (RR=6, RH=6, HH=4). 
 
GS activity: 
GS activity was measured using radiolabelled glucose [35] in the presence of low (0.02 mM), 
medium (0.17 mM) and high (8 mM) G6P concentrations; this enables the calculation of fractional 
velocity of the enzyme, %FV (comparison of medium to high G6P activities) and G6P-independent 
activity, I-form (comparison of low to high G6P values)[35]. These calculations enable 
 7 
investigation of the regulation of GS by G6P (%FV) and by phosphorylation (independent of G6P 
concentrations) (I-form) [35-37]. Briefly, 20 µg of homogenised muscle (RR n=12, RH n=13, HH 
n=4) was placed into wells of a 96 well plate (Nunc) in duplicate and 40 µl of each of 3 different 
glucose concentration reagents was added (final glucose concentrations of 0.02 mM, 0.17 mM or 
8 mM). Samples were incubated with the glucose reagent for 25 minutes at 37 oC and then 50 µl 
of the mixture was added to wells of Unifilter 96 well plates (Whatman) containing 200 µl 66% ice-
cold ethanol in ddH20 water. The plates were then incubated at -20 oC for 2 h and subsequently 
washed in ice-cold 66% ethanol 5 times. Plates were then dried for 15 minutes at 37 oC and 75 
µl of Microscint 40 scintillation fluid (Perkin Elmer) was added to each well before counting using 
a top-count NXT scintillation counter (Perkin Elmer).  
 
Muscle homogenisation:  
For total GS expression, homogenates were prepared from 50 mg of snap frozen muscle tissue 
dissected free of any visible fat or connective tissue and crushed using an ice-cold pestle and 
mortar. The powder was then dissolved in 1 ml of protein extraction buffer containing phosphatase 
inhibitors, heated at 100 oC for 5 minutes and subsequently centrifuged (16000g for 5 minutes at 
4 oC). The supernatant was removed and its protein concentration measured using the Pierce 
BCA protein assay.  
 
For phosphorylated isoforms of GS and upstream kinases, a modified extraction method was 
performed. 40 mg of frozen muscle was cut into small pieces and submerged in 600 ul of protein 
extraction buffer, before homogenising using a Qiagen TissueLyser (2 x 30 seconds at 30000 
Hz). The samples were then rotated end over end for 1 h at 4 oC and protein concentration was 
subsequently determined as above.  
 
Total glycogen synthase expression:  
Whole muscle protein homogenates were separated using 8% acrylamide gels and transferred 
onto nitrocellulose membranes (Amersham). Total GS expression was measured using a rabbit 
monoclonal antibody to the C-terminus of human glycogen synthase (Clone EP817Y; Epitomics; 
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1: 10000) and membranes were co-blotted with a mouse monoclonal antibody to human desmin 
(Clone D33, Dako; 1: 50000). Secondary antibodies were HRP-conjugated goat antibodies (either 
anti-rabbit or anti-mouse; BioRad; 1:5000). All antibodies were incubated for 1 hour at room 
temperature. Chemiluminescence was measured with the ECL-prime kit (Amersham) and 
Amersham Hyperfilm ECL (GE Healthcare). Assay linearity was confirmed through pilot 
experiments via loading of increasing amounts of protein per lane (results not shown). Films were 
digitised using a Stylus Photo RX640 printer and scanner (Epson, Hemel Hempstead, UK) 
alongside a 21-step transmission step wedge (Stouffer Graphic Arts, Mishawaka, USA).  The 
mean grey intensity values from equal rectangular areas of each region of the step wedge were 
quantified in ImageJ (NIH, Bethesda, USA). Total GS expression was calculated as a ratio to 
desmin expression to control for loading. 
 
Phosphorylated GS isoform expression:  
Muscle protein samples were separated using 8% acrylamide gels and then transferred using a 
semi-dry technique (Amersham TE77) onto a PVDF membrane (Millipore).  Sheep polyclonal 
primary antibodies were those used previously against phosphorylation epitopes of sites 1b (2 
µg/ml), 2+2a (4 µg/ml) and 3a+b (1 µg/ml) of GS [35, 38]. The relevant HRP-conjugated 
secondary antibodies were used (Dako; 1:5000). All antibodies were incubated for 1 hour at room 
temperature. Chemiluminesence was measured using Luminata Forte HRP chemiluminescent 
subrstrate (Millipore). After quantification using ImageLab software (Biorad), membranes were 
stripped of antibodies and then re-incubated with a total GS antibody as previously described to 
normalise the data. Results are presented as a ratio to total GS expression.  
 
GLUT4, GSK3  and AMPK phosphorylation and expression: 
Using the same technique as per phosphorylated isoforms of GS, total GLUT4 (Pierce; 1:1000), 
total GSK3 D transduction Laboratories; 1:500) and AMPK (1; 1:5000, 2; 1:15000 and 
1; 1:1000, as described by Woods et al. [39]; 2:1:3000 as described by Durante et al. [40] and 
pAMPK Thr172; 1:1000 from Cell Signalling) expression levels were measured in whole muscle 
protein homogenates. Antibodies directed at the 1 and 3 subunits did not detect the equine 
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protein. All primary antibodies were diluted in 2% skimmed milk and incubated overnight at 4 oC 
and all secondary antibodies were incubated for 45minutes at room temperature. The relevant 
HRP-conjugated secondary antibodies were used (Dako; 1:5000). GLUT4 and GSK3 expression 
was quantified in muscle protein samples using -actin (Sigma; 1:8000) as a loading control. 
AMPK expression was calculated and normalised according to a standard curve derived from 
protein homogenates of known quantities as is custom for this assay [41]. Chemiluminesence 
was measured using Luminata Forte HRP chemiluminescent substrate (Millipore) and quantified 
using ImageLab software (BioRad). 
 
Statistical analysis: 
Data calculations and statistical analysis were performed using GraphPad Prism (Version 6.0). 
Due to the small sample size for the homozygous mutant group, non-parametric statistics were 
performed and statistical significance was assessed via a Kruskal-Wallis test and Dunn’s post-
hoc multiple comparison test. Results were considered statistically significant when P<0.05.  
Pearson’s correlation was used to examine association between continuous variables.   
 
Homology modelling 
X-ray crystal structures of S. cerevisiae Gsy2p in the basal state (PDB code 3NAZ; 3 Å resolution) 
and G6P-bound state (PDB code 3NB0; 2.41 Å resolution) provided the templates for homology 
modelling of equine GS. The full-length sequence of equine GS was retrieved from Genbank 
(accession ACB14276) and sequence aligned with S. cerevisiae Gsy2p using Clustal Omega [42]. 
MODELLER software [43] was used to generate 50 models of both the basal and bound 
tetrameric forms of equine GS. In both cases the internal scoring function of MODELLER was 
used to select 10 models that were visually inspected and submitted to the VADAR webserver 
[44] for assessment of stereochemical soundness in order to select a single best model. The 
R309H mutation was introduced into both models using SwissPDBViewer [45]. Model figures 
were generated using PyMOL (DeLano Scientific, San Carlos, CA, U.S.A.). 
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GS baculovirus cloning and expression 
Wild-type GS and mutant R309H GS cDNAs were cloned into the PH promoter of the pFastBac 
dual vector (Invitrogen).  Subsequently the equine glycogenin (GYG1) cDNA was subcloned into 
the p10 promoter of both the wild-type GS*pFastBac and the R309H mutant Gs*pFastbacs, 
allowing co-expression of the active form of equine GS with equine glycogenin in Spodoptera 
frugiperda Sf9 insect cells. Each of the cloned insert sequences in each vector was verified with 
Sanger sequencing.  Western blot analysis of harvested insect cells from each of 3 different 
clones of mutant and wild type GS inserts was then used to confirm the expression of wild-type 
GS and R309H GS along with glycogenin. 1 litre culture of these cells  were grown and cell pellets 
harvested by Kinnakeet Biotechnology  
Purification of recombinant horse glycogen synthase 
The insect cell pellet was resuspended and lysed in 50 mL of extraction buffer containing 50 mM 
Tris-HCl, pH 7.8, 300 mM NaCl, 0.1% Triton X-100, 2 mM ethylene-diamine-tetra-aceticacid 
(EDTA), 1 mM Benzamidine, 0.5 mM phenylmethanesulfonyl fluoride (PMSF), 10 mM β-
mercaptoethanol (BME).  The crude cell extract was centrifuged at 35,000 rpm in a Beckman Ti-
45 rotor for 30 minutes at 4˚C and the supernatant was collected. To the clarified cell lysate, 
ethanol (kept at -80˚C prior to use) was slowly added under constant stirring to a final 
concentration of 30%. This process is done in an ice/salt broth so that the temperature stays 
between -1 and -5˚ C, ensuring complete precipitation of the endogenous insect cell glycogen (no 
additional glycogen was added). The suspension was then centrifuged at 9000g for 60 min at -
3˚C. The supernatant was discarded and the glycogen pellet was resuspended in 100 ml of 
loading buffer containing 50 mM Tris-HCl, 300 mM NaCl, 1 mM Benzamidine, 0.5 mM PMSF and 
2 mM BME. The resuspended pellet was then loaded onto a Concanavalin-A (Sigma) column. 
After washing the column with 20 column volumes of loading buffer, the protein was gradient 
eluted with glucose (0-400 mM). The fractions that had GS activity (in the presence of 10 mM 
G6P) was pooled and then dialyzed extensively against a buffer containing 50 mM Tris-HCl, 300 
mM NaCl and 2 mM BME to remove the free glucose. The protein was then concentrated and 
mixed with glycerol to a final concentration of 35% and stored at -20˚ C for long term usage [46].  
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Specific activity and activity ratio measurement 
Glycogen synthase activity was measured in the recombinant enzymes by the method of Thomas 
et al. which quantifies the amount of 14C-glucose transferred from 14C-labelled UDP-Glucose to 
glycogen over a period of 15 min at 30˚C [47]. Standard reaction conditions used 4.44 mM UDP-
Glucose and 6.67 mg/ml of glycogen. Activity was measured both in the presence or absence of 
10 mM G6P. The activity ratio is the ratio of the activity in the absence of G6P to the activity in 
the presence of 10 mM G6P. Protein concentration was measured by Bradford’s method, using 
bovine serum albumin as a standard. Prior to use, rabbit liver glycogen type-III was deionized by 
passing it through TMD-8 hydrogen and hydroxide form mixed bed exchanger resins.  
Enzyme Kinetics for UDP-Glucose and Glucose-6-Phosphate 
For the UDP-Glucose (UDPG) titrations, 7 different concentrations of UDPG (0.1 mM to 15 mM 
for the WT enzyme and 0.05 mM to 6 mM for the mutant R309H enzyme) were used keeping the 
glycogen concentration constant at 6.67 mg/ml either in the presence or absence of 10 mM G6P.  
Eight different concentrations of G6P were used for the G6P titrations under standard reaction 
conditions. 
Kinetic data analysis 
The enzyme kinetic data were analyzed with using SigmaPlot (v12.3). The activation curves for 
G6P were fitted to the 4 parameter logistic curve and the S0.5 values were obtained from these 
fits. The substrate saturation curves were fitted to the standard Michaelis-Menten equation v= 
Vmax*[S]/(Km+[S]), where v is the reaction rate, [S] is the substrate concentration, Vmax is the 
maximum rate achieved by the system and Km is the substrate concentration at half maximum 
velocity. The Vmax and Km values were obtained from these fits and the results represent the mean 
of 3 separate experiments. 
 
Results 
Breed and signalment data 
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There was no difference in age, sex or breed of the three genotyped groups used for this study. 
Signalment data is provided in table S1.   
 
Glycogen content, GS activity and total GS expression.  
Horses with the R309H mutation (heterozygote (RH) and homozygote (HH)) had significantly 
higher glycogen content in skeletal muscle than control (RR) horses (Figure 1A), although there 
was no difference between glycogen content in muscle from PSSM1-homozygote and PSSM1-
heterozygote horses. The higher glycogen content of mutant horse muscle was accompanied by 
higher GS activity in muscle samples from homozygotes (HH) compared to samples from 
heterozygotes and between homozygotes (HH) and WT controls (RR) in the absence (0.02 mM 
G6P) and presence (0.02 mM) of G6P respectively (p=0.04, p=0.03) (Figure 1B and 1D) but there 
was no difference in total maximal GS activity between genotypes (p=0.20, data not shown). 
Thereby suggesting an increased sensitivity to regulation by G6P.  There was no difference 
between total glycogen synthase protein expression in muscle samples in each of the genotyped 
groups (Figure 1C). 
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Figure 1: A) Glycogen content of wet weight muscle samples from WT (RR)(n=7), PSSM1-
heterozygotes (RH)(n=8) and PSSM1-homozygotes (HH)(n=4) horses.  (median +/- min/max 
values, box represents interquartile range; RR vs. RH p=0.005, RR vs. HH p= 0.041, *p<0.05).  
B) Glycogen synthase activity shown as fractional velocity (FV) and D) l-form activity. 
There was an increase in I-form activity between heterozygotes (RH) and PSSM1-homozygotes 
(HH) samples (p=0.04) and an increase in FV between PSSM1-homozygotes (HH) and WT 
controls (RR) (p=0.03) (median +/- min/max values, box represents interquartile range, RR (n= 
12), RH (n=13), HH (n=4) *p<0.05). C) Total glycogen synthase expression in muscle 
homogenates showed no significant differences between the genotypes for expression of total 
GS (p=0.98), 
 
Phosphorylation of GS 
Mutant horse muscle samples had greater phosphorylation at site 2+2a than WT samples (Figure 
2B; p=0.009), in a relationship that suggested dependency on mutant allele number. However, 
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there were no detectable differences in levels of phosphorylation at the other target sites (1b and 
3a+b) on GS between the genotypes (Figure 2A and 2C). 
 
Figure 2: Western blot analysis of phosphorylated GS expression from skeletal muscle 
homogenates. There were no significant differences between the genotypes for expression of A) 
p1b isoform (p=0.48) and C) p3a+b isoform (p=0.17). There was significantly more 
phosphorylation at site p2+2a (B) in PSSM1-homozygotes compared to control horses (RR) 
(p=0.009) and there was a trend suggesting a dependence on mutant allele copy number. (Mean 
+/- SEM, RR (n=12) RH (n=13) HH (n=3) *p<0.05). 
 
GLUT4, GSK3  and AMPK expression 
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There was no difference in GLUT4 or GSK3β protein expression between different genotypes 
(data not shown). However, there was significantly higher levels of AMPK1 protein in the 
homozygous mutant samples compared to WT controls (Figure 3A; p=0.04) and a trend towards 
higher phosphorylated AMPK (pAMPK) in homozygous mutant muscle samples compared to WT 
and heterozygotes (Figure 3E), although this did not reach significance (p=0.13). There was a 
highly significant and strong association between AMPK1 expression and pAMPK (Figure 3F; 
R2=0.66, p<0.0001). There was also significantly lower AMPK1 expression in homozygous 
mutant samples compared to heterozygotes (Figure 3C; p=0.03) but not compared to WT 
controls.  
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Figure 3:  AMPK subunit and phosphorylation expression from skeletal muscle extracts. 
There were no significant differences in AMPK2 (p=0.15) or AMPK2 (p=0.28) expression 
between different genotypes (B and D). There was a significant increase in AMPK1 expression 
in homozygous mutant samples (HH) compared to heterozygotes (RH) and WT controls (RR) (A; 
p=0.04) and a significant decrease in AMPK1 expression in the homozygous mutant samples 
(HH) compared to the heterozygotes (C; p=0.03). There was a significant and strong correlation 
between AMPK1 and pAMPK (F; R2=0.66, p<0.0001). 
 
GS activity is dependent on its phosphorylation; in particular phosphorylation of sites 3a, 3b and 
2+2a and is highly dependent on glycogen content via negative feedback [35]. Due to the 
significant increase in phosphorylation at site 2+2a, correlation coefficients were calculated 
between site 2+2a phosphorylation and glycogen content and GS activity.  Muscle glycogen 
content was weakly but significantly correlated with expression of the 2+2a GS isoform (R2=0.23, 
p=0.04) however there was no significant association between phosphorylation at site 2+2a and 
GS activity (data from whole cohort;  not shown).  
 
Glycogen synthase homology modelling   
The residues resolved in the G6P-bound crystal structure of yeast Gsy2p and the corresponding 
region of equine GS share 55% sequence identity (Figure 4). Conserved residues include the 
binding determinants of G6P and maltodextrin. In addition, the R309 residue of horse GS is 
conserved as R298 in yeast Gsy2p (Figure 4). Therefore Gsy2p structures with and without G6P 
bound provided suitable structural templates for homology modelling equine GS as a 
homotetramer with basal and active conformations, respectively (Figure 5A and  5B).  
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Figure 4: Sequence alignment of equine GS (Genbank accession ACB14276) and yeast 
Gsy2 (sequence in PDB ID 3NB0). Red star: R309 in equine GS and the location of the PSSM1-
associated R309H mutation. Magenta circles: predicted phosphorylation sites. Blue triangles: 
binding residues of glucose-6-phosphate. Diamonds: binding residues of maltodextrin (yellow: 
sites 1 and 2; green: sites 3 and 4).  
 
 
As a first step in understanding the structural effects of the R309H mutation, the environment 
around R309 was inspected in the wild-type GS models. In both basal and active GS models, 
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R309 is distal from the G6P and maltodextrin binding sites (Figure  5A and 5B) and is therefore 
not predicted to form a direct binding contact for either substrate. Nevertheless, R309 is located 
on the C-terminal end of an α-helix that contains four residues (H291, Q294, H297, K301) that 
are G6P binding determinants. In addition, R309 is positioned adjacent to a pair of α-helices that 
use a coiled-coil interaction to form the major interface between subunits of the tetramer. Indeed, 
conformational transition between basal and active states involves translation and rotation around 
this central tetrameric interface [26] (Figure 5A and B).   
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Figure 5: Homology models of equine GS. (A) Basal and (B) active-state equine wild-type GS 
model tetramers are shown as ribbons with monomers coloured different shades of grey. 
Residues in space-fill are R309 (red), G6P-binding contacts (blue) and maltodextrin-binding 
contacts (yellow: sites 1 and 2; green: sites 3 and 4). The 309 position and local charged residues 
are shown as sticks for WT GS [(C) basal; (D) active-state] and the PSSM1-associated R309H 
mutant [(E) basal; (F) active-state]. Also shown as sticks are the corresponding residues in the 
crystal structures of yeast Gsy2p [(G) basal; (H) active-state]. Salt bridge interactions are shown 
as green dashes. 
 
R309 in the GS models and the corresponding R298 residue in the yeast Gsy2p structures make 
similar interactions (Figure 5C-H). Gsy2p R298 forms a salt bridge with the side chains of D295 
in the basal state (Fig 5G). This interaction is lost in the active state (Figure 5H) and, whereas 
R298 forms no new interactions, its former interaction partner, D295, instead forms a salt bridge 
with residue R376. R376 is located on the adjacent α-helix that forms the aforementioned coiled-
coil configuration of the enzyme subunit interface. A similar state-dependent switch in salt bridges 
is found with equine WT GS. R309 engages in a salt bridge with E306 and, as with Gsy2P, this 
interaction is lost in the active state where E306 is instead available to form a salt bridge with 
K387.   
 
The R309H mutation was introduced into GS models and the predicted outcome was the 
elimination of the salt bridge interaction with E306 in the basal-state conformation (Figure 5E). 
Release of E306 from an interaction with the 309 position may instead allow it to interact with the 
adjacent K387 even in the basal state of the mutant enzyme.  
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GS kinetics 
Recombinant equine GS was then used to compare WT and mutant enzyme kinetics and marked 
differences were detected (Table 1). 
Table 1: Comparison of kinetics of WT and mutant (R309H) GS enzyme. Values given are 
the averages ±SEM from 3 separate experiments.  
Protein Km UDPG  
(-G6P) 
Km UDPG 
(10mM G6P) 
Vmax UDPG 
(-G6P) 
Vmax UDPG 
(10mM G6P) 
Vmax/Km 
(-G6P) 
Vmax/Km 
(10mM G6P) 
S0.5 G6_ 
(4.4mM UDPG) 
WT GS 2.4 ±0.2 1.6 ±0.1 0.05 ±0.01 3.1 ±0.1 0.023 ± 0.002 2.0 ±0.2 3.0 ±0.4 
R309H GS 0.48 ±0.01 0.18 ±0.02 0.72 ±0.06 1.9 ±0.1 1.5 ±0.3 11 ±2 0.24 ±0.03 
 
These analyses reveal that the mutant enzyme behaves as if it is nearly fully active even in the 
absence of its allosteric activator, G6P as is shown by the significantly lower Km and increased 
Vmax in the absence of G6P (Table 1).  
 
Figure 6: Glucose-6-phosphate titration curves for enzyme activity of the WT and R309H 
mutant enzyme. These curves show that the mutant enzyme has much higher enzyme activity 
at much lower concentrations of G6P and reaches its maximal activity at much lower G6P 
concentrations. (Mean +/- SEM on a logarithmic scale, n=3 repeats) 
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The G6P titration curves for the WT and the R309H mutant enzymes show that the mutant 
enzyme is nearing maximal activation at G6P concentrations that the WT enzyme is barely 
activated (Figure 6). 
Table 2: Specific activity of WT and R309H mutant glycogen synthase in absence and 
presence of G6P (n=3).  
 
Specific activity –G6P 
(umol/min/mg) 
Specific activity 10mM G6P 
(umol/min/mg) 
Activity ratio 
WT GS 0.04 
 
2.33 
 
0.02 
 
R309H GS 0.68 
 
1.63 
 
0.41 
 
  
The low activity ratio seen in the WT enzyme is similar to that seen in baculovirus generated 
human GS [48] and the R309H mutant enzyme shows an approximately 20 fold higher activity 
ratio (Table 2), due largely to the marked activation that occurs in the mutant enzyme, in the 
absence of G6P.  
 
Discussion 
PSSM1, caused by a missense mutation in the equine GYS1 gene [8] is histopathologically 
characterised by increased amylopectate and glycogen in skeletal muscle fibres [49]. Here, we 
investigated the protein structure, glycogen content, GS expression, regulation and activity in 
skeletal muscle samples and in mutant and wild type recombinant enzymes, in order to determine 
whether the increased GS activity in PSSM1-affected muscle, reported by McCue et al. [8] was 
associated with altered enzyme expression, altered upstream regulation or a conformational 
change with possible constitutive activation. Our results reveal that the R309H founder mutation, 
responsible for this highly prevalent equine myopathy, present in over 20 breeds worldwide, is 
caused by constitutive activation; furthermore, we propose a feasible structural mechanism based 
on our modelling analyses.  
 
Similar to previous results in another affected breed, we have shown that mutant draught horses 
have increased muscle glycogen storage [50] despite normal GLUT4 transporter expression [50]. 
There was no difference in total GS expression between controls and PSSM1-affected horses, 
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but PSSM1-affected homozygotes had increased GS activity. GS in skeletal muscle from 
homozygous mutant horses had increased G6P-independent activity, consistent with data from 
McCue et al., who detected higher GS activity, irrespective of G6P concentration, in PSSM1-
affected Quarter Horses [8]. As GS activity is inversely correlated to the extent of site 2+2a GS 
phosphorylation in normal muscle [35, 38, 51], the higher enzyme activity in mutant horses cannot 
be explained by inappropriate (i.e. reduced) GS phosphorylation in mutant animals, since affected 
horses showed significantly more GS phosphorylation at sites 2+2a, (and no difference in 
phosphorylation at other sites). However, as would be expected in normal muscle [36], PSSM1-
affected horses had increased phosphorylation at site 2+2a, in the presence of elevated muscle 
glycogen, most likely reflecting a normal physiological attempt to reduce enzyme activity [35, 51-
53]; indeed, the high GS activity in mutant horses occurs despite the phosphorylation and 
increased expression of the principal upstream kinase for phosphorylation at site 2+2a (AMPK). 
This lack of correlation suggests that the mutant enzyme is not regulated by lowered activity when 
phosphorylated at site 2+2a. 
 
It is notable that in our study, certain effects were only detectable in PSSM1-homozygotes 
compared with controls, rather than between heterozygotes and controls. This might relate to an 
exaggerated (compensatory) effect of protein derived from the normal allele in heterozygotes or 
might simply reflect a more modest phenotype that was not detectable in the number of samples 
analysed. In contrast, McCue et al. reported differences between PSSM1-heterozygotes and WT 
controls [8]; which might relate to the higher proportion of glycolytic fibres seen in their Quarter 
Horses compared with our draught horses: glycogen accumulation tends to be most prominent in 
glycolytic fibres [54]. 
  
The phosphorylation sites of muscle GS are located on the N- and C- termini of the enzyme [55, 
56]. We were unable to use homology modelling to investigate these sites as there are no 
corresponding regions resolved in the yeast Gsy2p structures. Nevertheless, the region around 
R309 was modelled (Figure 5) and, although not predicted to form a binding contact for G6P or 
maltodextrin (Figure 5A and 5B), this residue is positioned at a pivotal position near the tetrameric 
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interface of the enzyme and is located on an α-helix that harbours 4 G6P binding residues. 
Therefore, a structural perturbation at the 309 position could influence the position of the 
conformational equilibrium making it easier to adopt the active conformation. Modelling indicates 
that in the enzyme’s basal state, R309 engages in a salt bridge with E306 whereas in the active 
state E306 forms an alternative salt bridge with K387 (Figure 5C and D). These salt bridge 
interactions might be important for stabilising the conformation of their respective functional 
states. We therefore propose that the effect of the R309H mutation, which is predicted to eliminate 
the basal-state salt bridge (Figure 5E), likely shifts the conformational equilibrium of the enzyme 
to the active state and reduces its tendency to adopt an inhibited state (Figure 5F). Interestingly, 
the residue adjacent to R309 is conserved as a glycine in both equine GS (G310) and yeast 
Gsy2p (G299) and its mutation results in increased Gsy2p activity [17]. This glycine is located at 
a turn at the C-terminal end of the helix containing R298 (equivalent to equine R309) and G6P 
binding contacts. It is therefore positioned to function as a typical glycine-hinge residue and the 
reported mutation-associated change in enzyme activity [15], provides further evidence that 
structural deviations in this region can produce constitutive activation. 
 
Taken together, the increased activity detectable in horse muscle, seems most likely to be a 
constitutive change in the mutant enzyme’s function, similar to that of the yeast mutant that also 
fails to respond appropriately to phosphorylation [8, 17] and also fails to respond as expected to 
increased glycogen content [57]. In order to test this hypothesis, enzyme kinetic studies were 
performed using purified recombinant protein. These studies confirmed that the mutant enzyme 
was almost fully active at low G6P concentrations (Table 1): i.e. it is constitutively active. The 
activity ratio of the WT equine enzyme was similar to that seen of human GS purified in a similar 
manner; further, there was no detectable difference in the extent of phosphorylation between the 
WT and mutant recombinant enzymes (data not shown) that could explain these significant 
differences in enzyme kinetics. Our data therefore confirms that the R309H mutation associated 
with PSSM1 is a true gain of function mutation.  
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In summary, our work provides further evidence that support findings of a previous study [8] that 
revealed that that PSSM1-associated R309H GYS1 mutation results in increased glycogen 
content and GS activity in skeletal muscle. We now show that this elevated activity occurs despite 
hyperphosphorylation at site 2+2a and increased expression of AMPK, and for the first time, we 
suggest through predictive modelling a potential mechanism by which this occurs  Additional 
work is needed to explain all the phenotypic features of this equine disorder, including the 
intermittent rhabdomyolysis seen in some affected horses. However, our results suggest that 
therapeutic modification of AMPK activity, might be ineffective in mutant animals, as increased 
GS phosphorylation does not reduce the mutant enzyme’s hyperactivity; instead, efforts aimed at 
direct enzyme inhibition might be more effective. Finally, dysregulation of GS or other related 
enzymes should be considered in humans and other animals with glycogen storage diseases of 
unknown origin, particularly when a dominant mode of inheritance is identified; indeed, this 
common equine disease represents a large animal model for evaluation of treatments aimed at 
reducing polyglucosan formation in skeletal muscle [33], a feature of a number of important, but 
comparatively rare, human myopathic disorders.  
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Supplementary data 
Table S 1: Breed and signalment data for horses used in this study.  
 RR (n=12) RH (n=13) HH (n=4) 
Age (mean+/- SD) 10 (3.3) 9.7 (3.1) 9.3 (3.4) 
Sex    
Male 6 6 2 
Female 6 7 2 
Breed    
Belgian 5 7 2 
Percheron 7 6 2 
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Figure S1: Example western blots. A) Glycogen synthase antibodies, B) upstream kinases and 
actin and C) AMPK antibodies as optimised for use in equine muscle lysates.  
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